Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Anna V.
Anna V. Eliseenkova, Stamford, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20110190207 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 08-04-2011 |
Anna V. Ivshina, Singapore SG
| Patent application number | Description | Published |
|---|---|---|
| 20120004135 | IDENTIFICATION OF BIOLOGICALLY AND CLINICALLY ESSENTIAL GENES AND GENE PAIRS, AND METHODS EMPLOYING THE IDENTIFIED GENES AND GENE PAIRS - A method of obtaining cut-off expression values should be selected so as to maximise the separation of the respective survival curves of the two groups of patients. Pairs of genes are statistically significant genes are generated by generating a plurality of models, each of which represents a way of partitioning a set of subjects based on the optimal cut-off expression values of the pair of genes. Those gene pairs are identified for which one of the models has a high prognostic significance. Novel survival significant gene sets forming functional modules which could be used to develop specific prognostic and predictive tests are derived. | 01-05-2012 |
Anna V. Kukekova, Ithaca, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20090061448 | METHOD FOR IDENTIFYING OCULOSKELETAL DYSPLASIA IN DOGS - Provided are methods for identifying dogs as likely to be genetically normal, carriers of, or affected with Oculo-skeletal dysplasia (OSD) by determining the presence or absence of a drd2 COL9A2 mutation and/or a drd1 COL9A3 mutation. Also provided is a method for selective breeding of dogs and kits useful for carrying out the methods of the invention. | 03-05-2009 |
| 20090176225 | DIAGNOSTIC TEST FOR COLLIE EYE ANOMALY - The invention relates to a method for identifying dogs which are genetically normal, heterozygous for, or homozygous for the mutation primarily responsible for Collie eye anomaly (CEA). The method comprises the steps of obtaining a biological sample from a dog and testing DNA in the biological sample for the presence or absence of a 7.8 kilobase deletion within chromosome 37 in which the CEA mutation is located. No deletion is indicative of a normal dog. A deletion on one allele of chromosome 37 is indicative of a dog that is heterozygous for the CEA mutation. A deletion in both alleles of chromosome 37 are indicative of a dog that is homozygous for the CEA mutation. Also provided is a kit for identifying a dog as normal, heterozygous for, or homozygous for the CEA mutation. | 07-09-2009 |
Anna V. Piterina, Limerick IE
| Patent application number | Description | Published |
|---|---|---|
| 20110091925 | Processing of nanoparticles - Ligand-capped nanoparticles are dispersed in an organic solvent. There is then phase transfer of the nanoparticles introducing into the organic solvent an aqueous solution of polymer surfactant dissolved in water. The organic solvent and the aqueous solution are then mixed until the polymer forms micelles which encapsulate the nanoparticles in assemblies. The resultant nanoparticle assemblies in an aqueous phase may be used for any of a range of desired applications. It has been found that the assembly size can be tuned by control of any or a combination of method parameters such as concentration of polymer surfactant, and/or temperature of the phase change reaction, and/or rate of mixing, such as rotational rate of stirring. The nanoparticle assemblies find particular application as fluorescent biomarkers. | 04-21-2011 |
Anna V. Tourovskaia, Mountlake Terrace, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20100279268 | METHOD FOR CREATING PERFUSABLE MICROVESSEL SYSTEMS - A method for creating networks of perfusable microvessels in vitro. Cells including cell types capable of sprouting are seeded | 11-04-2010 |